Tom Brady Teams Up With eMed to Help More Americans Access GLP-1 Weight Loss Drugs

Tom Brady is stepping into a new role. It’s not on the football field this time. The NFL legend now serves as chief wellness officer at eMed, a digital health company. Their mission: get GLP-1 weight loss medications into the hands of more American workers.

Brady recently joined eMed CEO Linda Yaccarino on Fox Business’s The Claman Countdown to discuss the partnership. Notably, their pitch doesn’t target individual consumers scrolling through ads. Instead, they’re going after employers, since companies already provide health coverage to most working Americans.

Brady didn’t mince words about the scale of the problem. He called obesity a national epidemic. Furthermore, he said the goal is to make wellness more accessible than ever before.

So what exactly are GLP-1 drugs? These medications, including semaglutide and tirzepatide, mimic a hormone your gut naturally produces called GLP-1. This hormone slows digestion and helps you feel full longer. It also improves how your body manages insulin.

The FDA has approved certain versions of these drugs for type 2 diabetes. Other formulations treat chronic weight management, though only for patients meeting specific body mass index requirements. Either way, you can’t simply walk into a pharmacy and buy them. They require a prescription and ongoing medical supervision.

Here’s where the employer angle makes sense. Yaccarino noted that more than 60% of Americans get health insurance through their jobs. As a result, workplaces become a logical entry point for expanding access to expensive medications, especially given the out-of-pocket costs many patients face.

eMed’s strategy is straightforward: convince employers that covering GLP-1 drugs is worth the investment. The argument works both ways. Employees get healthier, and companies potentially save money by avoiding costlier health problems down the line, like heart disease and diabetes complications. Brady echoed this point, saying the approach cuts costs for businesses while genuinely improving people’s health.

It’s not quite that simple, though. Coverage often depends on insurance details that most people never consider, such as prior authorization rules or formulary restrictions. Medicare, for instance, has historically resisted covering weight loss drugs, even though it treats diabetes prescriptions differently. This inconsistency across payers is exactly the gap employer-sponsored programs are trying to fill.

Supply presents another challenge. GLP-1 medications have faced shortages for months at a time. Demand simply outpaced what manufacturers could produce. Consequently, the FDA has been monitoring the situation closely. One concern stands out: if employer wellness programs pull too heavily from limited supply, diabetes patients who depend on these same drugs could face access problems.

Compounded versions of these medications add another layer of complexity. Cheaper alternatives popped up during shortages, and the FDA raised concerns about their purity and dosing accuracy. Programs like eMed’s typically avoid this risk by sticking to FDA-approved formulations only.

Yaccarino says the company wants to bring Brady’s disciplined athletic mindset into corporate wellness. Ultimately, the goal is reducing chronic disease across the workforce over time.

Whether this actually works long-term remains an open question. Success will likely depend on how well employees stick with treatment. Coverage generosity matters too. So does regulatory clarity as these programs continue to scale.